Vinva Investment Management Ltd Lowers Holdings in Biogen Inc. $BIIB

Vinva Investment Management Ltd decreased its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 34.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 38,704 shares of the biotechnology company’s stock after selling 20,158 shares during the quarter. Vinva Investment Management Ltd’s holdings in Biogen were worth $5,361,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BIIB. Vanguard Group Inc. lifted its stake in shares of Biogen by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 17,290,651 shares of the biotechnology company’s stock valued at $2,171,533,000 after purchasing an additional 257,812 shares during the last quarter. State Street Corp increased its position in shares of Biogen by 1.0% during the 2nd quarter. State Street Corp now owns 7,468,807 shares of the biotechnology company’s stock worth $938,007,000 after purchasing an additional 71,897 shares during the last quarter. Geode Capital Management LLC raised its holdings in Biogen by 1.9% in the 2nd quarter. Geode Capital Management LLC now owns 3,918,150 shares of the biotechnology company’s stock valued at $490,089,000 after buying an additional 71,286 shares during the period. Invesco Ltd. lifted its position in Biogen by 2.4% in the second quarter. Invesco Ltd. now owns 2,320,126 shares of the biotechnology company’s stock valued at $291,385,000 after buying an additional 55,119 shares during the last quarter. Finally, Norges Bank acquired a new position in Biogen in the second quarter valued at about $284,358,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen will present new spinal muscular atrophy (SMA) data, including long‑term high‑dose nusinersen results and Phase 1b salanersen data as Phase 3 studies begin — news that supports the company’s SMA pipeline and could boost long‑term revenue potential if later trials read out favorably. Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
• Positive Sentiment: The New England Journal of Medicine published first data suggesting disease‑modifying potential for zorevunersen (Stoke Therapeutics collaboration) in Dravet syndrome, supporting the ongoing global Phase 3 EMPEROR study — a favorable scientific read that can increase confidence in Biogen’s partnered pipeline assets. The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
• Positive Sentiment: Proposed legislation (H.R. 7336, the ALS Better Care Act) would expand Medicare coverage and payments for ALS‑related services and incentivize clinical trial participation — a policy tailwind that could improve access and reimbursement for ALS therapies and indirectly benefit Biogen’s neurology franchise. New Bill: Representative Janice D. Schakowsky introduces H.R. 7336: ALS Better Care Act
• Neutral Sentiment: Analyst / investor pieces and fund letters have highlighted Biogen as an attractive long‑term holding (coverage in InsiderMonkey/Yahoo) — supportive for investor interest but not an immediate catalyst. What Makes Biogen (BIIB) an Attractive Long-Term Holding?
• Neutral Sentiment: Recent short‑interest reports show anomalous data (zero shares / NaN increases and a days‑to‑cover of 0.0), indicating reporting noise rather than a clear short‑selling pressure signal — treat these items as unreliable until clarified. (Internal short‑interest entries)
• Negative Sentiment: Despite positive pipeline and data releases, shares are down today — likely reflecting profit‑taking after recent gains, thin trading (volume below recent average), and market focus on near‑term revenue/guidance rather than later‑stage trial data. No new negative company‑specific regulatory or financial disclosures were reported in the entries provided.

Biogen Price Performance

Shares of BIIB opened at $184.87 on Monday. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $202.41. The firm’s 50 day moving average price is $183.08 and its 200 day moving average price is $165.46. The company has a market cap of $27.13 billion, a P/E ratio of 20.98, a PEG ratio of 1.47 and a beta of 0.15. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last released its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. The company had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The firm’s quarterly revenue was down 7.2% on a year-over-year basis. During the same period in the prior year, the business earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, research analysts forecast that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Priya Singhal sold 2,660 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the sale, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.18% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on BIIB shares. Piper Sandler lifted their price target on shares of Biogen from $157.00 to $177.00 and gave the company a “neutral” rating in a research report on Monday, February 9th. Royal Bank Of Canada upped their price objective on shares of Biogen from $217.00 to $233.00 and gave the stock an “outperform” rating in a report on Monday, February 9th. Citigroup increased their price objective on shares of Biogen from $185.00 to $215.00 and gave the stock a “neutral” rating in a research report on Monday, February 9th. HC Wainwright lifted their target price on shares of Biogen from $194.00 to $228.00 and gave the company a “buy” rating in a report on Monday, February 9th. Finally, Canaccord Genuity Group boosted their target price on Biogen from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Twelve equities research analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $205.04.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.